ATRX (Adhera Therapeutics) Beginning Cash Position: $0.06 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATRX Adhera Therapeutics Inc ATRX
12 GF Score
Price $0.00
View Full Analysis

What is Adhera Therapeutics Beginning Cash Position?

Adhera Therapeutics ATRX 12 Beginning Cash Position is $0.06 Mil as of Sep. 2023. GuruFocus rates ATRX with a GF Score™ of 12/100.

Adhera Therapeutics's Beginning Cash Position for the quarter that ended in Sep. 2023 was $0.06 Mil.

Adhera Therapeutics's quarterly Beginning Cash Position increased from Mar. 2023 ($0.03 Mil) to Jun. 2023 ($0.07 Mil) but then declined from Jun. 2023 ($0.07 Mil) to Sep. 2023 ($0.06 Mil).

Adhera Therapeutics's annual Beginning Cash Position declined from Dec. 2020 ($0.05 Mil) to Dec. 2021 ($0.00 Mil) but then increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.08 Mil).

Adhera Therapeutics Beginning Cash Position Related Terms

Adhera Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Adhera Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adhera Therapeutics Beginning Cash Position Chart

Adhera Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 3.92 0.05 0.00 0.08

Adhera Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 0.13 0.03 0.07 0.06
ATRX
12GF Score
Adhera Therapeutics Inc ATRX
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adhera Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $0.06 Mil mean?
Adhera Therapeutics (ATRX) has a Beginning Cash Position of $0.06 Mil as of Sep. 2023. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Adhera Therapeutics and its competitors.
Is Adhera Therapeutics' Beginning Cash Position too high?
Adhera Therapeutics' current Beginning Cash Position is $0.06 Mil. Overall, Adhera Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Adhera Therapeutics' Beginning Cash Position compare to PKBO and ARDS?
Adhera Therapeutics' Beginning Cash Position of $0.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Adhera Therapeutics and its competitors. Adhera Therapeutics's current Beginning Cash Position is $0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adhera Therapeutics stock overvalued right now?
Adhera Therapeutics (ATRX) has a current Beginning Cash Position of $0.06 Mil. The current Beginning Cash Position is $0.06 Mil. Adhera Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Adhera Therapeutics (ATRX), the current Beginning Cash Position is $0.06 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adhera Therapeutics Business Description

Address 8000 Innovation Parkway, Baton Rouge, LA, USA, 70820
Adhera Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing advanced drug candidates through accelerated pathways. The company's pipeline includes MLR-1019 for Parkinson's disease and MLR-1023 for diabetes, both licensed from the Melior Discovery group. MLR-1019 (armesocarb) is a drug candidate targeting both movement and non-movement symptoms of Parkinson's disease, while MLR-1023 (tolimidone) is being developed for Type 1 diabetes and has undergone Phase 2a and 2b studies in Type 2 diabetes patients. It also explores additional drug development opportunities and maintains legacy assets such as CEQ508, an oral RNA therapy candidate for polyps associated with Familial Adenomatous Polyposis (FAP).
12GF Score

Get the complete analysis for ATRX

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price